Cargando…
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
Individuals <2 years and ≥50 years of age, as well as those with other specific risk factors, are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines have been developed against encapsulated bacteria such as Streptococcus pneumoniae to provide improved immune response...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281374/ https://www.ncbi.nlm.nih.gov/pubmed/25149825 http://dx.doi.org/10.1007/s10096-014-2208-6 |